Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B.

IF 1.5 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-06-13 DOI:10.5937/jomb0-56238

Xijie Lai, Guosheng Gao, Xiunong Jiang

{"title":"Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B.","authors":"Xijie Lai, Guosheng Gao, Xiunong Jiang","doi":"10.5937/jomb0-56238","DOIUrl":null,"url":null,"abstract":"Background: Chronic hepatitis B (CHB) remains a wide-spread and serious infectious disease, with its pathogenesis still not fully understood. Tenofovir Amibufenamide, a pro-drug of tenofovir, belongs to the class of nucleoside reverse transcriptase inhibitors and is used in the treatment of CHB. This study aimed to evaluate the efficacy and safety of Tenofovir Amibufenamide in treating HBeAg-positive CHB.Methods: A total of 60 patients diagnosed with HBeAg-positive CHB were randomly assigned to two groups: an entecavir (ETV) group (0.5 mg) and a Tenofovir Amibufenamide (TMF) group (0.25 mg), with 30 patients in each. After 24 months of treatment, renal function (serum creatinine, glomerular filtration rate), liver function (ALT , AST , total bilirubin), and inflammatory markers (TNF-a levels) were measured to assess the antiviral efficacy and safety profiles of the two treatments.Results: Patients in the TMF group exhibited smaller changes in serum creatinine and glomerular filtration rate, indicating less renal impairment compared to the ETV group. Furthermore, the TMF group demonstrated greater reductions in alanine aminotransferase (ALT) and total bilirubin (TBIL) levels, indicating superior improvement in liver function (P<0.05). TNF-a levels were significantly elevated in the ETV group, reflecting greater inflammatory activity, while the TMF group showed more controlled inflammation. Additionally, the TMF group experienced significantly lower hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA levels, showing superior antiviral efficacy. The incidence of adverse reactions was lower in the TMF group (3.3%) compared to the ETV group (13.3%), although the difference was not statistically significant (P>0.05).Conclusions: Tenofovir Amibufenamide demonstrated superior efficacy in improving liver function and reducing viral load in patients with HBeAg-positive CHB. Moreover, it had a minimal impact on renal function and presented a higher safety profile compared to entecavir. These findings suggest Tenofovir Amibufenamide as a promising alternative for the treatment of HBeAg-positive CHB.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"687-695"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357611/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-56238","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic hepatitis B (CHB) remains a wide-spread and serious infectious disease, with its pathogenesis still not fully understood. Tenofovir Amibufenamide, a pro-drug of tenofovir, belongs to the class of nucleoside reverse transcriptase inhibitors and is used in the treatment of CHB. This study aimed to evaluate the efficacy and safety of Tenofovir Amibufenamide in treating HBeAg-positive CHB.

Methods: A total of 60 patients diagnosed with HBeAg-positive CHB were randomly assigned to two groups: an entecavir (ETV) group (0.5 mg) and a Tenofovir Amibufenamide (TMF) group (0.25 mg), with 30 patients in each. After 24 months of treatment, renal function (serum creatinine, glomerular filtration rate), liver function (ALT , AST , total bilirubin), and inflammatory markers (TNF-a levels) were measured to assess the antiviral efficacy and safety profiles of the two treatments.

Results: Patients in the TMF group exhibited smaller changes in serum creatinine and glomerular filtration rate, indicating less renal impairment compared to the ETV group. Furthermore, the TMF group demonstrated greater reductions in alanine aminotransferase (ALT) and total bilirubin (TBIL) levels, indicating superior improvement in liver function (P<0.05). TNF-a levels were significantly elevated in the ETV group, reflecting greater inflammatory activity, while the TMF group showed more controlled inflammation. Additionally, the TMF group experienced significantly lower hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA levels, showing superior antiviral efficacy. The incidence of adverse reactions was lower in the TMF group (3.3%) compared to the ETV group (13.3%), although the difference was not statistically significant (P>0.05).

Conclusions: Tenofovir Amibufenamide demonstrated superior efficacy in improving liver function and reducing viral load in patients with HBeAg-positive CHB. Moreover, it had a minimal impact on renal function and presented a higher safety profile compared to entecavir. These findings suggest Tenofovir Amibufenamide as a promising alternative for the treatment of HBeAg-positive CHB.

查看原文本刊更多论文

血清hbeag阳性慢性乙型肝炎患者接受替诺福韦治疗后血清TNF-a和生物标志物水平。

背景：慢性乙型肝炎（CHB）是一种广泛传播的严重传染病，其发病机制尚不完全清楚。替诺福韦Amibufenamide是替诺福韦的前药，属于核苷类逆转录酶抑制剂，用于治疗慢性乙型肝炎。本研究旨在评价替诺福韦氨布芬胺治疗hbeag阳性CHB的疗效和安全性。方法：将60例确诊为hbeag阳性CHB患者随机分为恩替卡韦（ETV）组（0.5 mg）和替诺福韦氨布芬胺（TMF）组（0.25 mg），每组30例。治疗24个月后，测量肾功能（血清肌酐、肾小球滤过率）、肝功能（ALT、AST、总胆红素）和炎症标志物（TNF-a水平），以评估两种治疗的抗病毒疗效和安全性。结果：与ETV组相比，TMF组患者血清肌酐和肾小球滤过率变化较小，肾功能损害较小。此外，TMF组丙氨酸转氨酶（ALT）和总胆红素（TBIL）水平明显降低，表明肝功能有明显改善（P0.05）。结论：替诺福韦氨布芬胺在改善hbeag阳性CHB患者肝功能和降低病毒载量方面具有较好的疗效。此外，与恩替卡韦相比，它对肾功能的影响最小，安全性更高。这些发现表明替诺福韦氨布芬胺是治疗hbeag阳性CHB的一个有希望的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.